Peptris Raises ₹70 Crore to Accelerate AI-Powered Drug Discovery in India

Peptris Secures ₹70 Crore to Accelerate AI-Driven Drug Discovery in India

India’s deep tech and biotech ecosystem continues to gain momentum. In a significant development for the country’s pharmaceutical innovation landscape, drug discovery startup Peptris has raised ₹70 crore in fresh funding. The round saw participation from IAN Alpha Fund and Speciale Invest, two well-known backers of early-stage and deep technology ventures.

The funding marks a major milestone for Peptris as it aims to strengthen its AI-driven drug discovery platform, expand research capabilities, and accelerate the development of novel therapeutic molecules.

This investment not only boosts Peptris’ growth journey but also signals increasing investor confidence in India’s biotech and healthtech startup ecosystem.

Why This Funding Round Matters

Drug discovery is traditionally a long, expensive, and high-risk process. Bringing a new drug from concept to market can take years — sometimes over a decade — and require substantial capital investment.

Peptris is attempting to change that narrative by leveraging artificial intelligence (AI) and computational drug discovery tools to:

• Reduce drug development timelines

• Improve accuracy in molecule prediction

• Lower research and development costs

• Increase the success rate of clinical candidates

The ₹70 crore funding will help the company scale its technology infrastructure and scientific team while advancing its drug pipeline.

Understanding Peptris’ AI-Driven Drug Discovery Model

What Makes AI in Drug Discovery So Powerful?

Artificial intelligence is transforming pharmaceutical research. Instead of relying solely on traditional lab-based experimentation, AI systems can analyze massive biological datasets to:

• Identify promising molecular targets

• Predict drug interactions

• Optimize chemical structures

• Reduce experimental failures

Peptris operates at the intersection of biotechnology, computational science, and machine learning — a powerful combination in modern drug research.

The Role of IAN Alpha Fund and Speciale Invest

The participation of IAN Alpha Fund and Speciale Invest highlights the growing appetite for deep tech investments in India.

Why Deep Tech Investors Are Betting on Biotech

Investors in the biotech sector are typically drawn to:

• High entry barriers

• Strong intellectual property (IP) potential

• Global scalability

• Long-term value creation

Drug discovery startups, especially those integrating AI, offer scalable solutions with international market potential.

This funding round indicates that investors see Peptris as a promising player in the global pharmaceutical innovation space.

India’s Growing Biotech and HealthTech Ecosystem

India has traditionally been known as a global pharmaceutical manufacturing hub. However, the focus is now shifting toward innovation-driven drug development.

Emerging Trends in Indian Biotech

• AI-assisted drug design

• Precision medicine

• Biologics and specialty therapeutics

• Rare disease research

• Oncology-focused platforms

With strong technical talent, improving research infrastructure, and supportive startup policies, India is gradually building a competitive biotech ecosystem.

Peptris’ funding is a reflection of this larger transformation.

How the ₹70 Crore Will Be Utilized

Scaling a drug discovery platform involves multiple layers of investment. The fresh capital is likely to be used for:

1. Expanding R&D Capabilities

Enhancing laboratory facilities and computational infrastructure.

2. Advancing Clinical Pipelines

Moving promising molecules closer to clinical validation.

3. Hiring Scientific Talent

Bringing in researchers, data scientists, and AI specialists.

4. Strengthening Intellectual Property

Protecting innovations through patents and regulatory filings.

Each of these areas is critical in a sector where precision, compliance, and innovation intersect.

The Challenges of AI-Based Drug Discovery

While AI offers tremendous promise, the journey is not without obstacles:

• Regulatory complexities

• Clinical trial risks

• Long commercialization timelines

• Capital-intensive operations

• Scientific uncertainty

However, the advantage lies in speed and computational efficiency — reducing trial-and-error cycles that traditionally slowed down pharmaceutical innovation.

Global Opportunities Ahead

Drug discovery is a global market. Startups that successfully develop innovative molecules can:

• License compounds to global pharma companies

• Enter co-development partnerships

• Expand into international markets

• Pursue global clinical trials

If Peptris succeeds in validating its pipeline, it could position itself as a key contributor to global pharmaceutical innovation.

Why Investors Are Focusing on AI + Biotech

The convergence of AI and biotechnology represents one of the most powerful frontiers in innovation today.

Key reasons for rising investment include:

• Data-driven research acceleration

• Lower marginal cost of computational modeling

• Increased probability of clinical success

• Demand for new treatments in oncology and rare diseases

In many ways, AI is becoming the backbone of next-generation drug discovery platforms.

What This Means for Indian Startups

Peptris’ ₹70 crore funding round sends a strong message to the Indian startup ecosystem:

• Deep tech startups can attract serious capital

• Scientific innovation is investable

• Biotech is no longer limited to traditional pharma giants

• AI-led platforms are shaping the future of healthcare

For aspiring biotech founders, this development reinforces the importance of strong research foundations combined with scalable technology.

The Road Ahead for Peptris

With fresh funding secured, the company now enters a critical execution phase. Success will depend on:

• Efficient capital allocation

• Milestone-driven research progress

• Regulatory navigation

• Strategic partnerships

If executed effectively, Peptris could emerge as one of India’s leading AI-powered drug discovery startups.

FAQs

1. How much funding did Peptris raise?

Peptris raised ₹70 crore in its latest funding round.

2. Who invested in Peptris?

The funding round saw participation from IAN Alpha Fund and Speciale Invest.

3. What does Peptris specialize in?

Peptris focuses on AI-powered drug discovery and computational pharmaceutical research.

4. Why is AI important in drug discovery?

AI helps reduce development timelines, optimize molecules, and improve research efficiency.

5. How will the funds be used?

The capital will support R&D expansion, clinical pipeline development, talent acquisition, and infrastructure upgrades.

6. Is India becoming a biotech innovation hub?

Yes, India is gradually shifting from manufacturing-focused pharma to innovation-driven biotech research.

7. What are the risks in drug discovery startups?

High R&D costs, regulatory hurdles, and long development timelines.

8. What is deep tech investment?

It refers to funding in science-driven and technology-intensive sectors like biotech and AI.

9. Can Peptris expand globally?

Yes, successful drug candidates can be licensed or developed for international markets.

10. Why are investors interested in biotech startups?

Because of high intellectual property value, global scalability, and strong long-term growth potential.